Literature DB >> 8708531

Expression of IGF-I and IGF-binding protein genes in cirrhotic liver.

R J Ross1, S L Chew, L D'Souza Li, M Yateman, J Rodriguez-Arnao, A Gimson, J Holly, C Camacho-Hubner.   

Abstract

The liver plays a central role in the IGF-I axis producing the majority of circulating hormone and some of its binding proteins (IGFBPs). Cirrhosis of the liver is characterised by changes in IGF-I and IGFBPs associated with liver fibrosis and regeneration. We have studied steady state levels of mRNA for the genes in the IGF-I axis in normal and cirrhotic human liver, localised the most highly expressed gene, IGFBP-1, and measured circulating IGFBP-3 by radioimmunoassay (RIA), IGFBP-2 and IGFBP-3 by Western ligand blot (WLB), and protease activity for IGFBP-3 in cirrhotic patients. Messenger RNA for IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 was detectable by Northern blotting in normal and cirrhotic liver although there was considerable variation in expression. IGFBP-2 and IGFBP-3 tended to be more highly expressed in cirrhotic liver and IGFBP-1 was more highly expressed in normal liver, although there were no significant differences. In normal liver, in situ hybridisation localised IGFBP-1 to hepatocytes. In cirrhotic liver the regenerating nodules showed expression of IGFBP-1 while there was none in fibrotic tissue. Circulating IGFBP-3 levels were low as measured by RIA and WLB but protease activity was only found in one patient. IGFBP-2 levels, assessed by WLB, were similar to the normal serum pool. Our data show that key mRNAs involved in the IGF-I axis continue to be expressed in cirrhotic liver despite end stage liver disease. The low levels of IGFBP-3 do not appear to be due to reduced gene transcription or increased protease activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708531     DOI: 10.1677/joe.0.1490209

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

Authors:  L Gianotti; F Broglio; G Aimaretti; E Arvat; S Colombo; M Di Summa; G Gallioli; G Pittoni; E Sardo; M Stella; M Zanello; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

2.  The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma.

Authors:  Y Gong; L Cui; G Y Minuk
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

3.  Interaction of insulin-like growth factor-binding protein 2 with α2-macroglobulin in the circulation.

Authors:  Miloš Šunderić; Goran Miljuš; Olgica Nedić
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

4.  Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair.

Authors:  T Knittel; C Dinter; D Kobold; K Neubauer; M Mehde; S Eichhorst; G Ramadori
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

5.  Markers of liver regeneration-the role of growth factors and cytokines: a systematic review.

Authors:  Katrin Hoffmann; Alexander Johannes Nagel; Kazukata Tanabe; Juri Fuchs; Karolin Dehlke; Omid Ghamarnejad; Anastasia Lemekhova; Arianeb Mehrabi
Journal:  BMC Surg       Date:  2020-02-12       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.